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Abstract
Background: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US
Food and Drug Administration (FDA). There are several randomised clinical trials (RCTs) that have investigated the
efficacy and safety of tofacitinib in adult patients with rheumatoid arthritis (RA). A systematic review with a meta-
analysis of RCTs was undertaken to determine the efficacy and safety of tofacitinib in treating patients with RA.
Methods: Electronic and clinical trials register databases were searched for published RCTs of tofacitinib between
2009 and 2013. Outcomes of interest include 20% and 50% improvement in the American College of
Rheumatology Scale (ACR20 and ACR50) response rates, rates of infection, the number of immunological/
haematological adverse events (AEs), deranged laboratory results (hepatic, renal, haematological tests and
lipoprotein level) and the incidence of drug withdrawal.
Results: Eight RCTs (n = 3,791) were reviewed. Significantly greater ACR20 response rates were observed in patients
receiving tofacitinib 5 and 10 mg bid (twice daily) versus placebo at week 12, with risk ratios (RR) of 2.20 (95% CI
1.58, 3.07) and 2.38 (95% CI 1.81, 3.14) respectively. The effect was maintained at week 24 for 5 mg bid (RR 1.94;
95% CI 1.55, 2.44) and 10 mg bid (RR 2.20; 95% CI 1.76, 2.75). The ACR50 response rate was also significantly higher
for patients receiving tofacitinib 5 mg bid (RR 2.91; 95% CI 2.03, 4.16) and 10 mg bid (RR 3.32; 95% CI 2.33, 4.72)
compared to placebo at week 12. Patients in the tofacitinib group had significantly lower mean neutrophil counts,
higher serum creatinine, higher percentage change of LDL/HDL and a higher risk of ALT/AST > 1 ULN (upper limit
of normal) versus placebo. There were no significant differences in AEs and withdrawal due to AEs compared to
placebo.
Conclusion: Tofacitinib is efficacious and well tolerated in patients with MTX-resistant RA up to a period of
24 weeks. However, haematological, liver function tests and lipoproteins should be monitored. Long-term efficacy
and pharmacovigilance studies are recommended.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory arth-
ritis and a systemic autoimmune disease, which can lead to
long-term joint damage, loss of function and disability [1].
In addition to the symptoms of joint destruction such as
pain, swelling, or stiffness of the joints, those patients with
RA may also suffer from other extra-articular manifesta-
tions, namely rheumatoid nodules [2], interstitial lung dis-
ease [3], cardiac involvement [4], and Felty’s syndrome [5].
The onset of RA typically occurs between 30 to 50 years
age. In the United Kingdom, the highest incidence is ob-
served in people over 70 years of age [6]. It is estimated that
the adult prevalence of RA is 0.5-1% in Europe and 1% in
the United States [1,7,8]. Within two years of onset, ap-
proximately one third of people with RA are unable to con-
tinue with employment due to the disease [6]. The
mortality rate of those people with RA is approximately
twice of those without [9].
Guidelines for the management of RA have been issued
by the American College of Rheumatology (ACR) [7,10],
and by the National Institute for Health and Clinical Excel-
lence guidelines in 2009 (NICE CG79) [6]. It is suggested
that there are three main steps in the management of RA:
pharmacological, non-pharmacological and surgical treat-
ment [6,7].
Pharmacological treatment of RA generally includes:
non-steroidal anti-inflammatory drugs (NSAIDs), gluco-
corticoid treatment, disease-modifying antirheumatic drugs
(DMARDs), and biologic agents [7,10]. By treating inflam-
mation, relieving pain and/or suppressing the immune re-
sponse, NSAIDs and glucocorticoids are able to alleviate
some of the symptoms associated with RA. Currently,
DMARDs such as methotrexate (MTX) remain the main
treatment approach [7]. Antirheumatic biologics, including
the tumor necrosis factor (TNF) inhibitors such as
adalimumab or non-TNF inhibitors [10] are usually consid-
ered when the other treatment approaches are not suffi-
ciently effective. There are still about one third of patients
who have an unsatisfactory response to available treatments
[11]. Consequently, development of new drugs and therapy
for RA is needed.
Tofacitinib (CP-690550), also called tasocitinib [12] dur-
ing early development with the commercial name Xeljanz®,
is a new oral DMARD and an alternative to biologics. It
was approved by the U.S. Food and Drug Administration
(FDA) on 6 November 2012 [13]. It is a Janus Kinase (JAK)
inhibitor which primarily inhibits JAK1 and 3, with a re-
duced inhibition of JAK2 [14]. It is suggested that as a
JAK1/3 inhibitor, tofacitinib might suppress cytokine/che-
mokine expression and the immune activation through the
JAK/STAT interferon-dependent signaling pathway, thus
offering a promising target for the treatment of RA [15-17].
Tofacitinib is licensed to treat adult patients with ac-
tive RA in the United States, especially for those either
unable to tolerate MTX or biological therapies or who
have an inadequate response. During the development of
tofacitinib, a series of phase II [18-21] and phase III
[22-25] clinical trials were conducted in adult patients at
multiple treatment centres.
To our knowledge, no systematic review has been pub-
lished to evaluate the efficacy and associated AEs of
tofacitinib in the treatment of RA. In this study, we
undertook a systematic review with a meta-analysis of
randomised controlled trials (RCTs) to investigate the ef-
ficacy and safety of tofacitinib in treating patients with
RA.
Our primary objective is to compare the response rates
[20% and 50% improvement in the ACR scale (ACR20) and
(ACR50)] of patients receiving tofacitinib versus placebo or
adalimumab. The secondary objectives are i) to compare
the incidence of infections, immunological or haemato-
logical AEs in those patients receiving tofacitinib versus pla-
cebo; ii) to compare the laboratory findings in those
patients receiving tofacitinib versus placebo; and iii) to
compare the incidence of withdrawal from the trials in
those patients receiving tofacitinib versus placebo.
Methods
We performed this systematic review in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Statement [26]. We searched
EMBASE, the Cochrane Library and PubMed using key-
words as follows: (tofacitinib) OR (tasocitinib) OR (CP-690,
550). Trial registers: the metaRegister of Controlled Trials
(www.controlled-trials.com), the Clinical trials government
(ClinicalTrials.gov) and World Health Organization Inter-
national Clinical Trials Registry Platform (ICTRP) (http://
www.who.int/ictrp/en/) were also searched to identify po-
tentially relevant studies. All databases were searched on
March 1, 2013. Titles, abstracts and the content of the arti-
cles were screened to determine whether the articles met
the inclusion criteria. Reference lists from retrieved studies
were reviewed for the identification of potentially relevant
studies. The search result was presented in Figure 1.
Inclusion criteria
The inclusion criteria for this systematic review were
those published RCTs investigating the efficacy and
safety of tofacitinib in adult patients (aged 18 or above)
who had a diagnosis of active RA defined according to
the ACR 1987 revised criteria for RA [27]. The exclusion
criteria were conference proceedings as we were unable
to assess the quality of these studies. Studies examining
drug treatments other than tofacitinib were also ex-
cluded. Studies that did not report the primary out-
comes (ACR20/50 response rates) were also excluded.
Further evaluation on the full text was conducted for in-
clusion assessment.
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Outcome measures
The standardised response measurements for RA clinical
trials of antirheumatic drugs, the ACR20 response rate
and ACR50 response rate were selected as the primary
outcome measures [8,28].
Secondary outcomes included the number of patients
with infections, immunological or haematological AEs,
such as bronchitis, influenza, nasopharyngitis, pharyn-
gitis, rash, upper respiratory tract infection, urinary tract
infection and neutropenia. Laboratory parameters exam-
ined included the least squares mean changes in neutro-
phil count, haemoglobin levels and serum creatinine
levels, incidence of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) more than one times
upper limit of the normal range (ULN), mean percentage
changes of low-density lipoprotein (LDL) and high-
density lipoprotein (HDL). The incidence of patient
withdrawal from treatment was also a secondary out-
come of interest.
Data extraction
We performed the initial electronic database searches
and screened the published abstracts for eligibility. Full
texts were retrieved for potentially useful articles and
then screened for relevance. Those relevant articles were
then assessed independently by two reviewers for inclu-
sion in the meta-analysis.
The data relating to the primary and secondary out-
comes in all included studies were extracted by two in-
dependent reviewers and cross-checked by an additional
reviewer for data accuracy. Non-statistical data extracted
from the eligible studies included author, study setting,
study duration, doses of tofacitinib, possible concomitant
medication, sample size, mean scores on 3-variable Dis-
ease Activity Score in 28 joints (DAS28-3) using C-
reactive protein, mean scores on 4-variables (DAS28-4)
using the erythrocyte sedimentation rate, mean scores
on the Health Assessment Questionnaire disability index
(HAQ-DI), and mean number of swollen joints and ten-
der joints. Statistical data on ACR20 and ACR50 re-
sponse rates, AEs and number of patient withdrawals
were also extracted.
Methodological quality assessment
The risk of bias of the identified RCT articles was
assessed using the Cochrane Collaboration’s tool [29]
(Additional file 1: Table S1). Assessment was conducted
independently and cross-checked by additional reviewers
with discrepancies resolved by consensus.
Statistical analysis
Risk ratios (RR) and mean differences were calculated
for dichotomous and continuous outcomes respectively
(e.g. ACR response rates, AEs and laboratory findings).
Figure 1 Review flowchart (PRISMA flowchart).
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The DerSimonian and Laird random-effects model was
used to deal with possible heterogeneity between studies
[30]. I2 statistic was used to describe the proportion of
the variability that is due to heterogeneity rather than
sampling error. Analyses were based upon intention-to-
treat (ITT) or completer analysis when ITT data was not
available. When standard deviations of the outcomes
were not given, they were calculated using standard er-
rors and sample sizes. We were unable to assess publica-
tion bias by funnel plot due to the scant number of
included studies. All statistical analyses were conducted
using Review Manager 5.2 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012).
Apart from meta-analysis, the dose–response relation-
ship was also plotted to determine the efficacy of
tofacitinib at different doses at week 12. All studies were
described as international multicenter trials except Ta-
naka et al.’s study [18] which was conducted solely in
Japan. Therefore, sensitivity analysis was conducted by
removing Tanaka et al.’s study [18] to examine the pos-
sible effects of differences in ethnicity.
Results
Search results and study selection
Figure 1 summarises the review flowchart in accordance
with PRISMA statement [26]. The electronic search of
EMBASE, the Cochrane Library and PubMed yielded a
total of 283 studies. Four additional unpublished records
were identified in the ClinicalTrials.gov, each with a dif-
ferent ClinicalTrial.gov identifier from the published re-
ports (Additional file 2: Table S2). A total of 259 records
were screened after the removal of the duplicates. After
scanning the titles and abstracts, 216 records were re-
moved as they were not clinical trials of tofacitinib. Full
texts of 43 studies were retrieved for more detailed
evaluation, of which 34 were then excluded since they
were not related to the treatment of RA. Another study
was excluded as it investigated pain, physical functioning
and health status but not efficacy and safety measures of
tofacitinib in the treatment of RA [31]. As a result, eight
eligible studies were included in this systematic review,
contributing a total sample size of 3,791. A standardised
summary table of the included studies is presented in
Table 1.
Methodological quality
All studies stated that they were double-blind, however
half of the studies did not report the method of alloca-
tion sequence and concealment. Co-interventions and
baseline characteristics were similar for the tofacitinib
and placebo groups for all studies. All studies had poten-
tial risks of bias as some of the outcomes stated in the
trial protocol were not reported. Another potential bias
might be introduced by switching from placebo to active
medication in some patients previously receiving placebo
in four studies. This potential bias was addressed in two
studies using the method of imputation of no response,
with “advancement penalty” [22,23].
Efficacy
The doses used and the treatment duration are shown in
Figures 2 and 3. ACR20 response rates were found to be
significantly higher in those patients receiving tofacitinib
versus placebo at doses ≥3 mg bid. A non-significant
dose-dependent response trend was observed from 1 to
5 mg bid (Additional file 3: Figure S1). ACR20 response
rates were significantly greater in tofacitinib treatment
versus placebo at 5 mg bid (RR 2.20; 95% CI 1.58, 3.07)
and 10 mg bid (RR 2.38; 95% CI 1.81, 3.14) after
12 weeks of treatment. The higher ACR20 response rates
in patients receiving tofacitinib sustained at week 24 for
5 mg bid (RR 1.94; 95% CI 1.55, 2.44) and 10 mg bid
(RR 2.20; 95% CI 1.76, 2.75) (Figure 2). Moreover,
tofacitinib was also significantly more efficacious than
placebo as measured by ACR50 response rate (Figure 3).
ACR50 response rates were significantly greater in
tofacitinib treatment at 5 mg bid (RR 2.91; 95% CI 2.03,
4.16) and 10 mg bid (RR 3.32; 95% CI 2.33, 4.72) after
12 weeks.
For the efficacy measures which were only reported in
respective single studies, significantly higher ACR20 and
ACR50 response rates were observed in patients receiv-
ing doses ≥5 mg tofacitinib versus placebo at week 6, 12
and 24 (Additional file 4: Figure S2). A significantly
higher response rate was also observed in ACR50 for
3 mg tofacitinib versus placebo at week 24.
Fleischmann et al. [21] and van Vollenhoven et al.
[22] also compared the efficacy of tofacitinib with
adalimumab at month 3 and 6 respectively (Table 2). At
month 3, there was a statistically significant difference in
ACR20 response rate in patients receiving ≥5 mg bid
tofacitinib versus adalimumab. At the dose of 5 mg bid,
the RR of ACR20 and ACR50 response rates were 1.65
(95% CI 1.08, 2.53) and 1.95 (95% CI 1.00, 3.80) in pa-
tients receiving tofacitinib versus adalimumab respect-
ively. The corresponding figures at 10 mg bid were 1.97
(95% CI 1.32, 2.92) and 2.35 (95% CI 1.26, 4.38) respect-
ively. At month 6, there were no significant differences
in ACR20 response rates in patients receiving tofacitinib
versus adalimumab.
Safety
The most commonly reported infections and immune-
related AEs during the 12-week tofacitinib treatment
period are shown in Table 3. There were no statistically
significant differences in patients receiving tofacitinib
versus placebo in the incidences of infections, neutro-
penia and withdrawal due to AEs. However, significantly
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Table 1 Characteristics of randomised controlled studies included in this meta-analysis
Article Region Study
duration,
weeks
Possible concomitant medication Dose of
tofacitinib
No of patients
randomiseda
Mean
DAS28-3
(CRP)a
Mean
DAS28-4
(ESR)a
Mean HAQ-
DIa
Mean no of
swollen
jointsa
Mean no of
tender jointsa
Fleischmann
2012a [21]
United States;
Europe; Latin
American; the
Republic of
Korea
24 NSAIDs; antimalarial agents; opioids;
acetaminophen; oral glucocorticoids
1, 3, 5, 10,
15 mg bid
Total: 386 Placebo:5.6 Placebo:6.6 Placebo:1.54 Placebo:16.9 Placebo:25.9
Placebo: 59
tofacitinib: 54,
51, 49, 61, 57
tofacinitib:
5.5, 5.4, 5.6,
5.5, 5.5
tofacinitib:
6.5, 6.4, 6.6,
6.5, 6.5
tofacinitib:
1.57, 1.53,
1.40, 1.49,
1.62
tofacinitib:
16.7, 15.9,
17.4, 16.3,
16.9
tofacinitib: 27.0,
24.6, 27.1, 25.7,
25.9
adalimumab
40 mg qow: 53
adalimumab
40 mg qow:
5.4
adalimumab
40 mg qow:
6.3
adalimumab
40 mg qow:
1.44
adalimumab
40 mg qow:
14.9
adalimumab
40 mg qow:
24.1
Randomised
but not
treated: 2
Fleischmann
2012b [25]
United States;
Europe; Latin
America; Asia
24 NSAIDs; glucocorticoids; 5, 10 mg
bid
Total: 611 Placebo: 5.56 Placebo: 6.65 Placebo: 1.53 Placebo: 17.3 Placebo: 28.9
Placebob: 61,
61
tofacitinib:
5.68, 5.60
tofacitinib:
6.71, 6.70
tofacitinib:
1.53, 1.50
tofacitinib:
16.3, 17.0
tofacitinib: 29.4,
29.1
tofacitinib:243,
245
Randomised
but not
treated: 1
Kremer 2009 [20] United States;
Canada;
Europe; Latin
American
6
(treatment)
+ 6 (follow-
up)
NSAIDs; selective COX-2 inhibitors;
opioids; acetaminophen; oral
glucocorticoids
5, 15,
30 mg bid
Total: 264 Placebo: 6.0 NA Placebo: 1.7 Placebo:
20.01
Placebo: 30.3
Placebo: 65
tofacitinib: 61,
69, 69
tofacitinib:
6.2, 5.7, 5.9
tofacitinib:
1.7, 1.6, 1.6
tofacitinib:
21.1, 16.2,
19.5
tofacitinib: 32.3,
26.7, 29.3
Kremer 2012 [19] United States;
Europe; Latin
America
24 MTX (compulsory) 1, 3, 5, 10,
15 mg bid,
20 mg qd
Total: 509 Placebo: 5.3 Placebo: 6.1 Placebo: 1.20 Placebo: 15.7 Placebo: 21.6
Placebo: 69 tofacitinib:
5.5, 5.3, 5.1,
5.3, 5.4
tofacitinib:
6.4, 6.1, 6.1,
6.4, 6.2
tofacitinib:
1.58, 1.36,
1.44, 1.33,
1.41
tofacitinib:
6.5, 15.7,
14.1, 14.7,
15.3
tofacitinib:23.6,
22.8, 21.5, 24.8,
23.7
tofacitinib: 70,
68, 71, 74, 75
20 mg qd:
5.3
20 mg qd:
6.3
20 mg qd:
1.46
20 mg qd:
15.2
0 mg qd: 23.1
20 mg qd:
80Randomised
but not
treated: 2
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Table 1 Characteristics of randomised controlled studies included in this meta-analysis (Continued)
Tanaka 2011 [18] Japan 12 MTX supplemented with folic acid
(compulsory);
1, 3, 5,
10 mg bid
Total: 140 Placebo: 4.9 Placebo: 5.9 Placebo: 1.3 Placebo: 13.8 Placebo: 16.4
Placebo: 28
tofacitinib: 28,
27, 27, 26
tofacitinib:
5.0, 5.1, 5.0,
4.9
tofacitinib:
6.1, 6.1, 6.0,
5.9
tofacitinib:
1.1, 1.3, 1.2,
1.2
tofacitinib:
13.2, 15.1,
15.6, 15.1
tofacitinib: 16.4,
16.2, 17.8, 15.4
NSAIDs;selective COX-2 inhibitors;
glucocorticoids
Randomised
but not
treated: 4
van
Vollenhoven2012
[22]
North America;
Latin America;
Europe; etc.
52 MTX (compulsory) 5, 10 mg bid Total: 717 Placeboc: 5.6,
5.3
Placeboc: 6.6,
6.3
Placeboc: 1.5,
1.4
Placeboc:
16.9, 16.4
Placeboc: 26.6,
28.1
Placeboc: 56,
52
tofacitinib:
5.4, 5.4
tofacitinib:
6.6, 6.5
tofacitinib:
1.5, 1.5
tofacitinib:
16.7, 15.8
tofacitinib: 28.5,
26.1
tofacitinib: 204,
201
adalimumab
40 mg qow:
5.3
adalimumab
40 mg qow:
6.4
adalimumab
40 mg qow:
1.5
adalimumab
40 mg
qow:16.4
adalimumab
40 mg qow:
26.7
adalimumab
40 mg qow:
204
Burmester 2013
[24]
North America,
Europe, Latin
America, etc.
24 MTX (compulsory); antimalarial therapy;
No other DMARDs (non-biological or
biological) were permitted NSAIDs,
selective cyclooxygenase-2 inhibitors, or
glucocorticoids
5, 10 mg
bid
Total: 399 Placebo: 5.4 Placebo: 6.4 Placebo: 1.6 Placebo: 17.2 Placebo: 28.2
Placebob: 66,
66
tofacitinib:
5.4, 5.3
tofacitinib:
6.5, 6.4
tofacitinib:
1.6, 1.5
tofacitinib:
16.2, 16.6
tofacitinib: 28.4,
27.6
tofacitinib: 133,
134
Van der Heijde
2013 [23]
America,
Europe, Asia,
Australia
104 MTX (compulsory); NSAIDs; corticosteroids 5, 10 mg
bid
Total: 797 Placeboc:
5.14, 5.18
Placeboc:
6.25, 6.29
Placeboc: 1.4,
1.23
Placeboc:
14.0, 14.5
Placeboc: 23.3,
22.6
Placeboc: 81,
79
tofacitinib:
5.22, 5.20
tofacitinib:
6.34, 6.25
tofacitinib:
1.41, 1.39
tofacitinib:
14.1, 14.4
tofacitinib: 24.1,
23.0
tofacitinib: 321,
316
DAS28: Disease Activity Score for 28 joint counts; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire disability index; bid, twice daily; qd, once daily; qow, once every
other week; NSAIDs: non-steroidal anti-inflammatory drugs; MTX: methotrexate; COX-2: cyclooxygenase-2.
aNo. of patients in tofacitinib group are presented in ascending order of dose.
bPatients in placebo group were assigned to 5 or 10 mg tofacitinib after 3 months; Numbers are presented in ascending order of dose of tofacitinib after switch.
cPatients assigned to placebo were randomly switched to either 5 or 10 mg of tofacitinib if they did not reduce the number of swollen and tender joints by 20% after 3 months. All patients in the placebo group were
assigned in a blinded fashion to either 5 or 10 mg of tofacitinib after 6 months; Numbers are presented in ascending order of dose of tofacitinib after switch.
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fewer patients withdrew from tofacitinib than placebo
(RR 0.60; 95% CI 0.45, 0.78). Similarly, the patient with-
drawal rate due to lack of efficacy was significantly lower
in the patients receiving tofacitinib versus placebo (RR
0.18; 95% CI 0.09, 0.35).
The mean neutrophil count significantly declined in
patients receiving tofacitinib versus placebo. The mean
serum creatinine was found to be significantly higher for
tofacitinib 10 mg bid versus placebo. The mean percent-
age change of HDL/LDL was significant higher in pa-
tients receiving tofacitinib versus placebo. The RRs of
the mean changes of ALT > 1 ULN and AST > 1 ULN
were statistically significant (Additional file 5: Table S3).
Sensitivity analysis
The RR of ACR20 response rate did not significantly
change with the exclusion of data from Tanaka et al.
[18]. For the tofacitinib treatment at 3 mg bid, the RR
slightly reduced from 2.20 (95% CI 1.20, 4.04) to 1.65
(95% CI 1.18, 2.30), however, the heterogeneity was sig-
nificantly reduced to 0% (Additional file 6: Table S4).
Similarly, the RR of ACR20 response rate for the
tofacitinib treatment at 5 mg bid (2.20; 95% CI 1.58,
3.07) did not change significantly (1.94; 95% CI 1.55,
2.43) but led to a reduction in heterogeneity. Although
the inclusion of Tanaka et al. [18] led to substantial het-
erogeneity, it did not materially alter the conclusion. No
Figure 2 ACR20 response rates for different doses of tofacitinib at week 12 and week 24.
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data for ACR50 response rate was available for sensitiv-
ity analysis.
Discussion
We undertook a rigorous systematic review and meta-
analysis using independent reviewers for data extraction
and statistical analysis. To our knowledge, this is the first
systematic review of the RCTs investigating tofacitinib in
the treatment of RA and included all relevant published
RCTs to date. The meta-analysis of the clinical trials of
tofacitinib in adult patients with RA showed that the use
of tofacitinib 5 mg bid resulted in statistically significant
higher ACR20 and ACR50 response rates compared with
placebo. A non-statistically significant dose-dependent
effect was observed in tofacitinib treatment at 1, 3, 5 mg
bid while the effect appeared to be saturated when the
dose reached 5 mg bid. In consistent with our result, the
FDA has approved the clinical dose of 5 mg bid for the
treatment of adults with moderately to severely active
RA [32].
Apart from the comparison of efficacy in different
doses, our study also compared the efficacy of tofacitinib
with one of the biologics, adalimumab. However, similar
to many newly marketed drugs, most of the published
studies were placebo-controlled trials. Two clinical trials
comparing the efficacy of tofacitinib with adalimumab
Figure 3 ACR50 response rates for 5 mg bid and 10 mg bid of tofacitinib at week 12 and week 24.
Table 2 Risk ratios of ACR20/50 response rates of tofacitinib vs.40 mg adalimumab at month 3 [21] and 6 [22]
ACR20 ACR50
Dose of tofacitinib Sample size (tofacitinib, adalimumab) Risk ratio [95% CI] Sample size (tofacitinib, adalimumab) Risk ratio [95% CI]
Month 3
1 mg bid 54, 53 0.88 [0.52, 1.50] 54, 53 0.59 [0.23, 1.51]
3 mg bid 51, 53 1.09 [0.67, 1.80] 51, 53 1.25 [0.59, 2.63]
5 mg bid 49, 53 1.65 [1.08, 2.53] 49, 53 1.95 [1.00, 3.80]
10 mg bid 61, 53 1.97 [1.32, 2.92] 61, 53 2.35 [1.26, 4.38]
15 mg bid 57, 53 2.01 [1.35, 2.98] 57, 53 2.70 [1.46, 4.98]
Month 6,
5 mg bid 196, 199 1.09 [0.89, 1.33] N/A N/A
10 mg bid 196: 199 1.11 [0.91, 1.36] N/A N/A
bid twice daily; CI confidence interval; N/A, not applicable.
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were identified. Our findings showed that ACR20 and
ACR50 response rates were statistically significant higher
in patients receiving tofacitinib versus adalimumab at
month 3, except the ACR50 response rate of tofacitinib
5 mg bid treatment. However, the ACR20 response rate
of tofacitinib was similar to that of adalimumab in a
period of 6 months. Aaltonen et al. [33] recently
conducted a meta-analysis to compare the response rates
(ACR20 and ACR50) of TNF inhibitors with placebo
group. They reported the RR of ACR20 response rate at
month 3 were 2.24 (95% CI 1.63, 3.08) and 2.50 (95% CI
1.90, 3.30) at month 6. Asltonen et al.’s results are also
comparable to our results on tofacitinib 5 mg bid treat-
ment at month 3 (RR 2.44; 95% CI 1.58, 3.77) and at
month 6 (RR 1.87; 95% CI 1.42, 2.48). Similarly, RR of
ACR50 response rate at month 3 reported by Aaltonen
et al. was 4.16 (95% CI 2.44, 7.09) which is also compar-
able to ours in tofacitinib (5 or 10 mg bid) at month 3
(RR 3.05; 95% CI 2.25, 4.14). The current available evi-
dence seemed to support the efficacy of tofacitinib in the
short-term treatment of RA, which may be comparable
to TNF inhibitors. However, further head-to-head direct
comparison studies are needed to confirm the results.
Unlike the biologics which are administered by injec-
tion, tofacitinib is a small molecule which can be admin-
istered orally. Although tofacitinib is not currently
licensed for children, an oral treatment is likely to be
well received by children with MTX-resistant RA. In ac-
cordance with the requirements of the new European
and FDA paediatric regulations, the manufacturer
should plan on conducting paediatric clinical trials so
that data will be available in the future to guide the use
of tofacitinib in children.
In our meta-analysis, the results showed no statistically
significant difference in the outcome of AEs in the
tofacitinib group versus placebo but some laboratory abnor-
malities were observed in short-term studies. We found sig-
nificantly higher mean serum creatinine in the tofacitinib
group and it was also in line with a review reporting higher
incidence rate of blood creatinine elevation in tofacitinib
treatment group compared to comparator group [34].
However, this did not result in patient withdrawal at week
12 shown in our meta-analysis. Similarly, there was a sig-
nificantly higher risk of ALT/AST > 1 ULN in the
tofacitinib group versus placebo. One study reported that
four patients discontinued in tofacitinib treatment group
but none in the placebo group due to increases of AST and
ALT levels [18]. Moreover, tofacitinib has the potential to
cause immunosuppression, inducing serious infections and
malignancies. This possibility is supported by its pharmaco-
logical action which acts as a JAK1/3 inhibitor. A confer-
ence abstract showed a statistically significant higher risk of
infection due to the decrease in absolute lymphocyte
counts [35]. Significantly lower neutrophil counts were also
found in tofacitinib treatment versus placebo, but no pa-
tients’ discontinuation was reported. The most common
infection-related AEs reported in tofacitinib treatment were
upper respiratory tract infections, urinary tract infections
and nasopharyngitis [27]. Tuberculosis was also reported in
four patients receiving tofacitinib 10 mg bid treatment
[22,23,25]. With respect to malignancies, lung cancer
[22,23,25] and renal cell carcinoma [21] were descriptively
Table 3 Adverse events with tofacitinib at week 12 and withdrawal from trials
5 mg bid 10 mg bid
Adverse events No. of
studies
Sample size
(tofacitinib, placebo)
Risk ratio
[95% CI]
No. of
studies
Sample size
(tofacitinib, placebo)
Risk ratio
[95% CI]
Infection
Upper respiratory tract
infection
4 901, 522 1.12 [0.61, 2.05] 4 896, 522 0.77 [0.40, 1.49]
Urinary tract infection 4 901, 522 1.22 [0.58, 2.57] 4 901, 522 1.01 [0.45, 2.27]
Bronchitis 4 901, 522 0.80 [0.25, 2.56] 4 896, 522 1.01 [0.34, 2.96]
Nasopharyngitis 5 928, 550 1.57 [0.51, 4.83] 5 922,550 1.67 [0.82, 3.39]
Influenza 3 768, 390 0.37 [0.08, 1.64] 3 762, 390 1.25 [0.25, 6.20]
Pharyngitis 2 231, 136 0.01 [−0.01, 0.03] 2 227, 136 0.03 [−0.09, 0.14]
Immune system
Neutropeniaa 4 826, 482 1.41 [0.55, 3.61] 4 830, 482 1.73 [0.68, 4.38]
Rash 3 552, 296 0.32 [0.04, 2.61] 3 543, 296 2.51 [0.63, 9.93]
Withdrawal No. of studies Tofacitinib N (%) Placebo N (%) Risk ratio [95% CI]
All causes 5 158 (12.31%) 59 (16.71%) 0.60 [0.45, 0.78]
Adverse events 5 50 (3.89%) 8 (2.27%) 1.43 [0.68, 3.03]
Lack of efficacy 5 16 (1.25%) 20 (5.67%) 0.18 [0.09, 0.35]
bid twice daily; CI confidence interval; amild, 1500–1999 cells/mm3.
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reported in the included studies. Another conference ab-
stract summarising RCTs and long-term extension studies
reported higher incidence rate when the duration of expos-
ure to tofacitinib is longer. It also reported statistically sig-
nificant higher risk of lung cancer in the tofacitinib group
compared with the Surveillance Epidemiology and End Re-
sult database covering the general population [36]. How-
ever more studies are needed to confirm the above findings
and also investigate the risk of other malignancy associated
with long-term tofacitinib treatment. Apart from malignan-
cies, the European Medicines Agency also suggested that
cardiovascular problems (largely related to adverse lipid
profile) should be specifically monitored in patients with
RA in clinical trials [8]. A meta-analysis reported statisti-
cally significant higher risk of hypercholesterolaemia (RR
1.70; 95%CI 1.10, 2.63) in tofacitinib treatment group when
compared to the comparator group [34]. A significant in-
crease in LDL/HDL was also noted in our meta-analysis.
Of note, in one study [24], the results for changes in LDL/
HDL reported in the main text was not consistent with the
supplementary figures, hence was excluded from the ana-
lysis. Cardiovascular outcomes such as congestive cardiac
failure, chest pain and chest discomfort were also descrip-
tively reported in the included studies [19,21].
Despite the laboratory abnormalities, the clinical signifi-
cance was still unclear as too few patients discontinued and
no statistically significant difference was observed in all RRs
of AEs. However, long-term pharmacovigilance studies are
needed to explore the clinical significance on the laboratory
abnormalities and confirm the long-term safety.
Our results showed that more patients withdrew from
the placebo group than from the tofacitinib group
(Table 3). The above results can be explained by the fact
that significantly more patients in the placebo group
withdrew due to lack of efficacy. Although there was a
higher withdrawal rate due to AEs in the tofacitinib
group than that of placebo group, the difference was not
statistically significant. The above results further support
that tofacitinib has a favorable risk/benefit ratio for
short-term use.
There are several potential limitations in our meta-
analysis. Firstly, all published studies have reported statisti-
cally significant higher ACR20 and ACR50 response rates
in patients receiving tofacitinib when compared to placebo
and all these clinical trials were sponsored by the manufac-
turer. At the time of the analysis, we also identified four
more completed registered trials from the ClinicalTrials.gov
since 2010 but peer-reviewed published results were yet to
be available (Additional file 2: Table S2). Consequently, the
possibility of publication bias and time-lag bias cannot be
excluded. Although we have generated funnel plots to ac-
cess publication bias, the paucity of the literature makes it
difficult to warrant its reliability. Secondly, the patient in
the included studies all had an inadequate response to
MTX treatment, which may limit the generalisability of
study findings to DMARD naïve patients. Thirdly, there is
substantial statistical heterogeneity between studies in the
outcomes of ACR20 and ACR50 response rates. This ap-
parent heterogeneity was likely to be attributed to data
from a single study by the Tanaka et al. [18]. However, sen-
sitivity analysis showed that its exclusion resulted in reduc-
tion in heterogeneity without materially affecting the
overall conclusions. The setting of this study was similar to
all other studies in terms of concomitant medication and
study duration. However we observed a high RR of ACR20
response rate, which implied that the heterogeneity may be
due to the difference in study populations as this study was
conducted among the Japanese population only. The other
studies were conducted internationally, mainly in North
America. Pharmacogenomics studies are recommended to
investigate the apparent differences in efficacy.
In addition, some important information was not
reported in the included studies, which limit our further
understanding of the efficacy and safety of tofacitinib treat-
ment in some circumstances. First, data according to differ-
ent age groups should be reported. The manufacturer
reported that elderly people (≥65 years) receiving tofacitinib
might have a higher risk of developing serious infections
and more severe RA symptoms, which may render different
efficacy and safety of tofacitinib [27]. However, there was a
lack of published information reporting the outcomes of
this specific age group. Second, radiographic outcomes
such as erosions, joint space narrowing and Sharp van der
Heijde should be reported at least at baseline, during and at
the end of the trial for assessing the efficacy [10] but they
were not reported in the included trials.
Conclusions
In conclusion, tofacitinib is more effective than placebo
in the treatment of MTA-resistant RA up to 24 weeks.
Tofacitinib is well tolerated as no statistically significant
AEs impacting the immune or hematologic system were
observed in short-term studies compared with placebo.
Despite significantly lower neutrophil counts in
tofacitinib group, there were no associated treatment
withdrawals. However, further studies on long-term effi-
cacy and pharmacovigilance studies are still needed to
support long-term use.
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